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ABSTRACT  
In my thesis I discuss analysing drugs and medicines of abuse from whole blood, plasma and saliva. I 
go through different methods to analyse these matrices and previous studies where these matrices have 
been compared. I also deal with sample collection and different qualities of saliva for example drug 
transfer from blood to saliva. 
 
The objective of my thesis was to compare drug and medicine concentrations in whole blood, plasma 
and saliva in samples taken from people suspected of driving under the influence. The aim was to 
determine what kind of differences there are and do the results correlate between the matrices. Samples 
were collected from voluntary DUI (driving under the influence) drivers at the Helsinki University 
Department of Forensic Medicine with the cooperation of a forensic pathologist and the police. 
Samples were analysed in the Drug Research Unit of the National Public Heath Institute in Finland. 
 
I got samples from 28 voluntary suspected DUI driver and from these the comparable results there were 
for amphetamine, cannabinoids and benzodiazepines. Due to the small number of samples definite 
conclusions could not be made from the results but indicative results for amphetamines and 
benzodiazepines could be found. In whole blood and plasma there were only a few positive samples for 
cannabinoids so no comparison could be made with saliva. There were all together 14 amphetamine 
positive samples and according to these results the correlation between whole blood and plasma was 
very strong. Amphetamine concentrations in saliva were much higher than in whole blood and plasma 
but there was still some correlation between all the matrices. In benzodiazepines comparable results 
were found in six substances; diazepam, alprazolam, nordiazepam, oxazepam, clonazepam and 
temazepam. Whole blood and plasma had strong correlations for each of these substances. In 
comparison with saliva there was correlation with whole blood and plasma only in oxazepam, 
nordiazepam and temazepam. 
 
These results indicate that any of these matrices could be used to detect amphetamines from suspected 
DUI drivers. For other substances this study cannot give proper conclusions. Of the benzodiazepines 
analysed in this study the results are too narrow for saliva to be used reliably. Whole blood and plasma 
are both usable matrices for detecting benzodiazepines according to this study.   
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TIIVISTELMÄ 
Työssäni käsittelen huumaus- ja lääkeaineiden analysointia veri-, plasma- ja sylkinäytteistä. Käyn läpi 
erilaisia menetelmiä näiden matriisien analysoimiseksi sekä aiempia tutkimuksia, joissa eri matriiseja 
verrataan. Käsittelen myös näytteiden keräystä ja syljen ominaisuuksia kuten huumausaineiden 
siirtymistä verestä sylkeen. 
 
Työn tarkoituksena oli verrata huumaus- ja lääkeaineiden pitoisuuksia veri-, plasma- ja sylkinäytteissä 
rattijuopumuksesta epäillyiltä henkilöiltä otetuista näytteissä. Tavoitteena oli selvittää minkälaisia eroja 
eri matriisien välillä on ja kuinka ne korreloivat keskenään. Näytteet kerättiin vapaaehtoisilta 
rattijuopumuksesta epäillyiltä henkilöiltä oikeuslääkäriasemalla yhteistyössä oikeuslääkärin ja poliisin 
kanssa. Näytteet analysoitiin Kansanterveyslaitoksen huumetutkimusyksikön laboratoriossa. 
 
Näytteitä saatiin 28 vapaaehtoiselta ja niistä saatiin keskenään verrattavia tuloksia amfetamiinista, 
kannabiksesta ja bentsodiatsepiineista. Näytteiden vähäisen määrän vuoksi vahvoja päätelmiä tuloksista 
ei voinut tehdä, mutta suuntaa antavia tuloksia sain amfetamiinille ja bentsodiatsepiineille. Kokoveressä 
ja plasmassa oli niin vähän kannabispositiivisia näytteitä, että vertailua syljen kanssa ei voinut tehdä. 
Amfetamiinipositiivisia näytteitä oli kaiken kaikkiaan 14 ja näiden tulosten perusteella saatiin vahva 
korrelaatio kokoveren ja plasman välille. Amfetamiinipitoisuudet olivat syljessä huomattavasti 
korkeampia kuin kokoveressä ja plasmassa. Kokoveri ja plasma myös korreloivat jonkin verran syljen 
kanssa. Bentsodiatsepiinien ryhmään kuuluvista aineista verrattavia tuloksia oli kuudelle aineelle; 
diatsepamille, alpratsolamille, nordiatsepamille, klonatsepamille, oksatsepamille ja tematsepamille. 
Kokoverellä ja plasmalla oli vahva korrelaatio näiden kaikkien aineiden kohdalla. Sylki sen sijaan 
korreloi kokoveren ja plasman kanssa vain oksatsepamissa, nordiatsepamissa ja tematsepamissa. 
 
Nämä tulokset antavat viitteitä siitä, että mitä tahansa näistä matriiseista voitaisiin käyttää amfetamiinin 
analysoimiseen päihteiden alaisena ajamisesta epäillyiltä henkilöiltä. Muista aineista ei tämän 
tutkimuksen perusteella voi juuri tehdä johtopäätöksiä. Tutkituista bentsodiatsepiineista syljen osalta 
tulos on liian suppea, jotta sitä voitaisiin käyttää luotettavasti. Kokoveri ja plasma taas soveltuvat 
molemmat käytettäväksi bentsodiatsepiinien analysointiin tämän tutkimuksen valossa.        
Avainsanat 
 
kokoveri, plasma, sylki, huumaus- ja lääkeaineet 
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1 INTRODUCTION 
 
Drugs and medicines of abuse are known to impair the ability to drive a car and 
therefore deteriorating the road safety. Police may not see the state of the driver and ask 
for a drug test if alcohol cannot be shown in the breath test. Also drugs and medicines 
of abuse are often used together with alcohol and therefore are not detected. (Lillsunde, 
Pirjo - Luntiala, Pertti - Seppä, Heikki - Gunnar, Teemu – Hokkanen, Arto – Penttilä, 
Antti 2003, 3.) 
 
Internationally Finland belongs to the high road safety countries. It has been shown that 
generally deaths in traffic accidents have decreased in previous decades in Finland even 
though the traffic volume has increased. Alcohol’s share of serious accidents has been 
increasing and sadly with other intoxicants the statistics look even worse. From 1989 to 
the year 2002 the amount of traffic accidents involving at least one party under the 
influence of drugs or medicines increased five times. Still alcohol is the greatest risk in 
traffic but other substances must be taken in to account also. (Lillsunde et al. 2003, 7-9.) 
 
The objective of the EU road safety programme is to bisect the amount of the victims of 
traffic accidents in the EU-area by the year 2010. It has been shown that traffic safety 
has increased in the last decade and deaths in traffic have decreased in the EU-area. 
(Lillsunde et al. 2003, 9.) 
 
The title of my thesis is comparing the concentrations of drugs and medicines in whole 
blood, plasma and oral fluid samples of drivers suspected of driving under the influence. 
My thesis is part of the sub study of the EU-project DRUID (Driving Under the 
Influence of Drugs, Alcohol and Medicines).  The sub study is about comparing the 
levels of drugs and medicines in different matrices. 
 
This EU-project is conducted in Finland by the National Public Health Institute (KTL). 
It is done in cooperation with the Police and Helsinki University Department of 
Forensic Medicine. All the samples are analysed in the National Public Health Institute 
Drug Research Unit. The blood and plasma samples are analysed in the routine drug 
laboratory. The National Public Health Institute is in charge of all the sampling and 
analyses and they provide all the materials and supplies for this study.  
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The research problem investigates what kind of differences there are in drug levels 
when comparing whole blood, plasma and saliva samples that are taken at the same time 
from drivers suspected of driving under the influence of drugs, medicines or alcohol. 
These matrices are chosen because of their accessibility and possibilities. If the 
correlations between the matrices are good for example saliva could be used to 
determine drugs of abuse from drivers instead of blood. Blood and plasma are more 
traditional and already widely used matrices for detecting drugs of abuse. Collection 
and handling are well documented and the analysing method is similar for both. Saliva 
on the other hand is more an alternative matrix and it has several potential qualities. 
Ease of collection and handling makes it interesting matrix to take in to wider use in 
detecting abuse of drugs and medicines. 
 
Whole blood contains all the components of blood whereas plasma is the liquid portion 
of blood without blood cells. Plasma still contains some of the blood proteins.   
 
1.1 Aim of the study 
 
The objective of my thesis is to get information on the whole blood-plasma-oral fluid 
concentrations of different drugs and medicines. The samples are collected at the 
Helsinki University Department of Forensic Medicine from people suspected of driving 
under the influence of drugs or medicines and alcohol (DUI). The aim for the whole 
study is to get the samples from 300 DUI cases. In my thesis the amount of cases will be 
about 30 so the amount of samples will be about 90. 
 
This study will give information about the efficiency of traffic control of drugs and 
medicines. It can also give answers to the questions about the more reliable methods for 
monitoring driver’s impairment and whether the current method is the best. It may help 
in changing the opinions toward alternative matrices in DUI investigation. 
 
1.2 Implementation of the study 
 
The beginning of the study was to start taking samples at the Department of Forensic 
Medicine. As my development study for Stadia I organised a place for taking samples at 
the Department of Forensic Medicine and we started taking the samples in cooperation 
with MD Philippe Lunetta. The samples will be analysed with immunological methods 
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and GC–MS (gas chromatography-mass spectrometry). The whole blood samples are 
analysed in the routine lab since they are real police DUI samples. I will get the results 
when the analyses are ready and then according to the results I will decide what to 
analyse from the plasma. Whole blood samples will be analysed again together with the 
plasma samples according to the routine results. Whole blood is therefore analysed two 
times so that the results are from samples with similar storage conditions. The saliva 
samples will be analysed with a semi-quantitative method for all the substances that are 
included in the list of analyzed substances in DRUID-project. The list of these 
substances is in table 1. 
  
 
2 BACKGROUND 
 
The background of this study is very tightly tied on the DRUID-project since it belongs 
to the sub-study of the project. The methodology and ethics and purpose of this study 
are all defined by the DRUID-project. This study belongs to the area of road-safety and 
methodology of detecting the abuse of substances harmful in traffic. 
 
2.1  DRUID-project 
 
DRUID (Driving Under the Influence of Alcohol, Drugs and Medicines) is an EU-
Project involving 19 European countries: 17 EU countries and Norway and Switzerland. 
From these countries there are 37 research institutes taking part in the project. The 
DRUID-project consists of seven work packages. In several of these work packages 
biological samples are collected. These biological samples are for example whole blood, 
oral fluid and plasma. In the project the aim is to determine the prevalence of drugs of 
abuse and medicines in traffic and in accident victims, the accident risk caused by 
psychoactive substances, the medicines actions in healthy persons and patients, and the 
effect of drugs on driving capabilities. The biological samples collected are not the 
same in every country. Legislation and practises in every country are taken into account 
and samples are collected accordingly. The aim of this project is also to produce new 
information about ratios of drugs of abuse and medicines in whole blood, plasma and 
oral fluid, and levels in urine. The analyses will be done with immunological methods 
and GC–MS. In addition the aim is to find out whether the blood spot sample is suitable 
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for DUI sampling since it has been established in researches that cocaine can hydrolyse 
in whole blood samples. The whole project started 15.10.2006 and will finish 
14.10.2010. (Druid-tutkimussuunnitelma 2006.) 
 
2.2 DRUID Sub Study: Comparison of the Whole Blood-Plasma-Oral Fluid Ratios of 
Different Drugs and Medicines 
 
This particular sub study of the project is carried out in close cooperation with the 
police and Helsinki University Department of Forensic Medicine. When stopping a 
suspected DUI driver the police fill out an observation form in which they make an 
evaluation of weather, roadway and driving manner. They also mark up their 
observations made during the stopping. With the help of the observation form the police 
make decisions about the driver’s ability to drive the vehicle and decide whether the 
driver should be taken to the blood test.  
 
Police brings the suspected DUI drivers to the Department of Forensic Medicine for a 
blood test. The doctor taking the samples at the Forensic Medicine Department makes a 
clinical evaluation about the level of functional disorder of the driver and fills out the 
intoxication investigation form. The police’s observation form and doctor’s intoxication 
evaluation form are a part of normal preliminary investigation material and therefore 
normal practices when driving under the influence is suspected. The results of these 
forms have not been systematically compared with the findings of the blood samples so 
proper information of correspondence between these does not exist. In this study one of 
the interests is to compare the police’s and doctor’s evaluation form results to the actual 
level of drugs of abuse in blood. 
 
The aim in this study is to get in total of 300 suspected DUI drivers to participate in the 
research. Drivers are asked to sign a written consent for taking part in the research. 
Participation is completely voluntary and does not affect the drivers DUI detection or 
his position in court. The driver can refuse his participation in the study at any time. 
There is an identification sticker in the information form the driver receives with which 
he can retract his participation in the study. Personal identification information is 
removed from the samples so that the samples that have already been taken cannot be 
found with the personal data.  
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2.3 Drugs and Medicines Analysed In the Study 
 
There are 28 different substances that are analysed in DRUID. Here is a chart of those 
drugs and medicines and their cut-off limits. These are the cut-off limits defined by 
DRUID, the lowest concentrations of positive samples. Any concentration above these 
limits will be interpreted as a positive result. 
 
TABLE 1. Substances and their cut-off limits in DRUID (ng/ml) 
Substance Whole blood  
cut-off 
Plasma  
cut-off  
Saliva 
cut-off 
Ethanol 0,1 g/l - 0,1 g/l 
Morphine 10 10 20 
Amphetamine 20 20 25 
MDMA 20 20 25 
MDA 20 20 25 
Cocaine 10 10 10 
THC 1 1 1 
THC-COOH 5 5 - 
Diazepam 20 20 5 
Alprazolam 10 10 1 
Clonazepam 10 10 1 
Benzoylecgonine 50 50 10 
Codeine 10 10 20 
6-acetylmorphine 10 10 5 
Methamphetamine 20 20 25 
Methadone 10 10 20 
Oxazepam 50 50 5 
Nordazepam 20 20 1 
Zopiclone 10 10 10 
MDEA 20 20 25 
Lorazepam 10 10 1 
Flunitrazepam 2 2 1 
Zolpidem 20 20 10 
Temazepam 50 50 5 
Midazolam 10 10 1 
Phenazepam 20 20 1 
Nitrazepam 10 10 1 
Zaleplon 5 5 5 
 
 
3 ANALYSING THE SUBSTANCES 
 
There are several methods for determining the drugs of abuse in biological matrices. 
Here are outlined some of the methods and how research has evaluated the suitability of 
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certain methods for each respective matrix. Here are also some results that different 
researchers have found for the analysing methods. 
 
3.1 Determining Drugs of Abuse and Medicinal Drugs in Blood and Plasma 
 
Determination of drugs in blood is of great importance in clinical and forensic 
toxicology. Analyses are done for the actual substance and for some of its metabolites 
and degradation products. For screening drugs of abuse there are sensitive 
immunological methods available for many of the analytes. Mostly the screening and 
confirmation is done with gas chromatography-mass spectrometry (GC-MS) or liquid 
chromatography-mass spectrometry (LC-MS). (Kraemer - Paul 2007, 1415.) 
 
When comparing different methods for analysing certain drugs of abuse, Kraemer and 
Paul used papers written in English between 2002 and 2007. Their main perspective 
was to describe methods suitable for forensic toxicological determination. The methods 
they were interested in had to meet the expectations of being reliable and providing 
quantitative results. In the review they compared the determination methods for 
cannabinoids, opiates, amphetamines and amphetamine-derived designer drugs, cocaine 
and their metabolites. (Kraemer - Paul 2007, 1415-1435.) 
 
According to the Kraemer and Paul review there are several different immunological 
screening methods available. Positive immunoassay results must always be confirmed 
by a second independent method. This other method must be as sensitive as the 
screening method and provide the highest level of confidence in the results. Usually the 
confirmation is done by GC-MS or LC-MS. When the prevalence of positive samples is 
high, the screening should also be done by chromatographic procedures. (Kraemer - 
Paul 2007, 1416-1426.) 
 
3.1.1 Cannabinoids 
 
In the determination of cannabinoids there are several things to take into account. The 
primary psychoactive component of cannabis is THC. It is rapidly metabolised in to 
OH-THC and further to inactive THC-COOH. It is recommended to determine all of 
these from a toxicological point of view. THC is almost completely bound to plasma 
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proteins and its distribution into red blood cells is very poor and that’s why the 
concentrations in plasma and blood are not completely comparable. It should always be 
mentioned whether plasma or blood has been used in quantitative analysis. (Kraemer - 
Paul 2007, 1426-1427.) 
 
According to Kraemer and Paul GC-MS method is the most commonly used method for 
quantitative determination and confirmation of cannabinoids in blood and plasma. Most 
often methylation and silylation were chosen as derivatization method for GC-MS. 
Derivatization is used to increase thermal stability, sensitivity and to get more specific 
mass fragments of the target analytes in mass spectra. In addition to GC-MS, also an 
increasing number of methods based on LC-MS has been used for quantitation of THC 
and THC-COOH.  One advantage of LC-MS is that no derivatization of the extracts is 
required. (Kraemer - Paul 2007, 1426-1427.) 
 
3.1.2 Opiates 
 
In many European countries opioids, mainly heroin, accounted for about 60% of all 
recorded illegal drug treatment requests in 2004 according to Kraemer and Paul. In their 
review they concentrated in the analysis of morphine, codeine and heroin and their 
principal metabolites. (Kraemer - Paul 2007, 1428.) 
 
Heroin is quickly hydrolyzed to 6-MAM (6-monoacetylmorphine) and next to 
morphine. Morphine is also rapidly metabolized and its major metabolite is M3G 
(morphine-3-glucuronide). There have been several techniques to quantify morphine 
and its metabolites. Immunoassays are simple to handle but they fail to specify opiates 
from their glucuronides and should only be used as screening methods. (Kraemer - Paul 
2007, 1428.) 
 
According to Kraemer and Paul to overcome matrix interference in the determination of 
opiates procedures were applied for purification of bio matrices. In the whole blood 
analyses, protein precipitation with acetonitrile or methanol was often conducted. 
Several GC-MS methods for the analysis of opiates have bees described since 2002. 
LC-MS/MS technique has become popular for simultaneous determination of low 
concentrations of morphine, M3G and M6G. It provides better sensitivity than EI-GC-
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MS (electron impact-gas chromatography-mass spectrometry) which is also used as a 
method for the analysis of the opiates.  (Kraemer - Paul 2007, 1429.) 
 
3.1.3 Amphetamines 
 
Amphetamine and metamphetamine are strong stimulants of the central nervous system. 
They are drugs of abuse and also doping agents. When determining amphetamine and 
metamphetamine from blood the target analytes are the parent compounds, not 
metabolites. (Kraemer - Paul 2007, 1430.) 
 
Amphetamine-derived designer drugs have gained popularity and they are often used as 
“rave drugs”. They cause feelings of euphoria and energy and aspiration to socialize. 
These designer drugs are MDA, MDMA and MDEA. When determining the designer 
drugs in blood the target analytes are the parent compounds and for MDMA and MDEA 
also the metabolite MDA.  (Kraemer - Paul 2007, 1430.) 
 
According to Kraemer and Paul amphetamines can be analysed from blood with GC-
MS. It is also getting more popular to analyse amphetamines with LC-MS procedures. 
For routine analysis there are traditional alkaline LLE (liquid-liquid extraction) 
procedures and acylation using perfluoroacylated reagents followed by GC-MS 
detection in use. Peters et al. have presented a new method for simultaneous screening 
and quantitation of amphetamines and designer drugs in plasma. (Kraemer - Paul 2007, 
1430.) 
 
3.1.4 Cocaine 
 
In many parts of the world cocaine has become one of the most frequently used drugs of 
abuse. The most common routes for cocaine administration are intranasal, intravenous 
and through smoking. (Kraemer - Paul 2007, 1431.) 
 
Cocaine metabolizes quickly into many metabolites. The major metabolite 
benzoylecgonine (BZE) should be included in screening and quantitation from plasma 
according to Kraemer and Paul. Cocaine demands special care during analysis since it 
seems to have a tendency for hydrolysis and pyrolysis, extensive metabolism and 
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formation of thermo labile products. For determining cocaine, inhibition of plasma 
esterases by e.g. sodium fluoride is necessary. For a routine forensic laboratory the 
determination of cocaine and BZE may be adequate. (Kraemer - Paul 2007, 1432.)  
 
In testing for cocaine and its metabolites there are methods for GC-MS and LC-MS 
procedures. GC-MS may cause some problems when analysing cocaine after smoking 
crack. AEME (anhydroecgonine methyl ester) is formed during smoking but also in the 
GC injection port. This may cause false positive results for AEME. Thus LC-MS has 
proven to be a valuable tool for clarifying oxidative metabolism of cocaine. (Kraemer - 
Paul 2007, 1433.)  
 
3.1.5 Benzodiazepines 
 
Benzodiazepines are often prescribed drugs for treating many medical and psychiatric 
disorders. They are anticonvulsive, centrally muscle relaxing, sedative hypnotics and 
anxiolytic agents. Different benzodiazepines have different duration of action and 
potencies in these categories. There are several methods for analysing single 
benzodiazepine or a selective group of these analytes and a few for non-benzodiazepine 
hypnotic agents. These procedures that have been published lack the possibility for 
determination of both groups simultaneously. (Gunnar - Ariniemi - Lillsunde 2005, 175-
176.) 
 
A method has been presented for simultaneous screening of benzodiazepines in whole 
blood using GC with MS and electron capture detection (ECD). Most of the analytes 
were analyzed quantitatively and others semi-quantitatively. Gunnar et al. note that 
Kratzsch et al. have recently presented a method for quantitative analysis for these 
analytes from plasma using atmospheric pressure chemical ionization (APCI) liquid 
chromatography-mass spectrometry (LC-MS).  Quantitative methods for analysing 
benzodiazepines from whole blood, plasma or serum have recently included dual-
column GC, GC-MS, GC-tandem mass spectrometry (GC-MS/MS), liquid 
chromatography (LC), liquid chromatography-mass spectrometry, and liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). According to Gunnar et al 
GC-MS has remained the method of choice in many routine laboratories because of the 
separation efficiency, versatility, and ease of operation and maintenance. This method 
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offers also lower costs of the analysis and investment expenses compared to LC-
MS/MS. (Gunnar et al. 2005, 176.) 
 
According to Gunnar et al, when using GC based methods for analysing 
benzodiazepines the derivatization of polar functional groups containing reactive 
hydrogen agents atoms is very important. Silylating reagents are often used for 
derivatization since they are versatile, easy to prepare and can be injected directly into 
the GC-MS system. With use of derivatization increased thermal stability, sensitivity 
and more specific mass fragments of the target analytes in mass spectra are commonly 
achieved. (Gunnar et al. 2005, 176.)  
 
3.2 Determining Drugs of Abuse and Medicinal Drugs in Saliva 
 
Saliva is an alternative matrix for determining drug abuse. There has been a lot of 
interest toward salivary drug testing for several years and its possibilities are still 
unclear. Particularly saliva has been of interest for road-side testing for potentially 
intoxicated drivers and now it is in use for that. For forensic purposes the use of saliva 
is still limited. (Schramm – Smith – Craig - Kidwell 1992, 1; Samyn – Verstraete - van 
Haeren - Kintz 1999,40) 
 
For drug testing saliva is easy to collect non-invasively and collection can be done 
under supervision. Problems with saliva testing have been found to be variability in 
collection protocols and therefore in results. For example in road-side testing the sample 
volume can be very small. Also it has been known that the salivary concentrations are 
smaller than urine concentrations. The problem earlier was lack of commercialized 
immunoassay tests but now they are available. (Samyn et al. 1999, 40.) 
 
According to Samyn et al salivary drug concentration is defined by the route of 
administration, the salivary pH, the degree of plasma protein binding, and the 
physicochemical properties of the abused drug. They find that saliva might be a better 
tool than blood for testing potentially intoxicated drivers since the saliva/plasma ratio is 
so good. (Samyn et al. 1999,40) Schramm et al thinks that saliva is potentially better in 
indicating a state of intoxication than blood since it contains the free component of drug 
that is physiologically active. Many drugs are bound to proteins in blood and they are 
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not physiologically active but saliva is an ultra-filtrate of interstitial fluid and contains 
the free components of drugs. (Schramm et al. 1992, 1.)  
 
3.2.1 Formation of the Saliva 
 
Samyn et al recite three main functions of saliva to be: (1) the moistening of the mucous 
membranes of the upper aero-digestive area in order to ease speech and solubilise food 
to help swallowing, (2) to control the bacterial flora of the mouth and generate defence 
mechanisms, (3) to supply enzymes for food digestion and hormones, and other 
pharmacologically active compositions. The saliva is mostly produced by the major 
salivary glands. Saliva contains ordinary body fluid electrolytes. Primary saliva 
formation is situated in the end-pieces of the salivary glands. Formation of saliva is 
dependent on the active transport of one or more of the principal ions from the 
interstitial fluid to the acinar cells and the lumen. Water enters the lumen by osmosis. 
Saliva is mostly water (99%) and mineral salts. It also contains proteins and enzymes. 
Almost all of the organic compounds of plasma may be detected in saliva even though 
the total protein concentration in saliva is less than 1% of that of plasma. An adult 
produces saliva 500-1500 ml per day. (Samyn et al. 1999, 40-41.) 
 
3.2.2 Drug Transport In To Saliva 
 
Samyn et al describes the drug transport in to saliva. Before any drug can be released 
from plasma to saliva it must pass the capillary wall, the basal membrane, and the 
membrane of the glandular epithelial cells. They find that the following mechanisms 
occur since saliva is not a simple ultra filtrate of plasma: passive diffusion through the 
membrane; active processes against a concentration gradient; filtration through pores in 
the membrane; and pinocytosis. Most of the drugs seem to enter saliva by a simple 
passive diffusion process. This is dependent of the drug’s physicochemical 
characteristics which are pKa (indicates the strength of the acid; the higher the pKa 
value, the weaker the acid), liposolubility, molecular weight, and spatial composition. 
Also diffusion defining factors are the degree of plasma protein binding and the pH of 
both media.  The lipophilic drugs with a low degree of ionization can cross the barrier 
between plasma and saliva easily so that the concentration of saliva is a reflection of the 
non-protein bound plasma concentration. Nonetheless, for weakly basic drugs, the pH 
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of the saliva is the main importance for the concentrations discovered in saliva. (Samyn 
et al. 1999, 42.) 
 
3.2.3 Saliva Collection 
 
There are several methods for collecting saliva. For example the subjects can be asked 
to spit in to the vial or saliva can be collected by tilting the head forward allowing the 
saliva to flow freely into a container. There are also some special devices for saliva 
collection for example the Omni-Sal device with a sterile collection pad, transport tube 
and buffer solution. Different stimuli can be used to cause salivation for example 
chewing Teflon or chemical stimuli can be used with citric acid crystals or sour candy. 
However it might be better to use un-stimulated saliva since drug concentrations can 
decrease when salivary flow is increased. There are some limitations for this: social 
barrier to spitting may cause dry mouth, some drugs have been observed to cause 
diminished salivary flow, and there is often more froth than actual liquid so that 
sufficient sample is not obtained. (Samyn et al. 1999, 42.) 
 
3.2.4 Testing Saliva for Cocaine 
 
It has been established that cocaine can be detected from saliva also after intravenous 
administration so it is evident that cocaine enters the salivary glands from the blood 
circulation. Thus, the positive result is not just residue from nasal or oral administration, 
but still contamination of the buccal cavity after smoking or sniffing can have a 
significant effect on the salivary cocaine levels. Immunoassay can detect cocaine from 
saliva as long as 10 days after intake. According to Schramm et al the cocaine 
concentration in saliva is usually higher than in plasma. (Schramm et al. 1992, 4.) 
 
Samyn et al. noted that Thompson et al. had observed a good correlation between the 
salivary cocaine concentration and its plasma concentration. Cocaine half-life in saliva 
is known to be about 35 minutes which also correlates well with plasma half-life of 
about 40 minutes. Confirmation is usually done with GC-MS method although the 
detection time is shorter. Cocaine can generally be detected from saliva for several 
hours after administration by different routes. Analytical methods with detection limits 
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of 5 to 10 ng/ml are sufficiently sensitive and can detect also the metabolites that appear 
little later into the saliva.( Samyn et al. 1999, 43-44.) 
 
3.2.5 Testing Saliva for Cannabinoids 
 
There have been attempts to analyse THC from saliva since the early seventies. 
Analytical methods for cannabis detection from saliva have been first thin layer 
chromatography and later on different methods with for example HPLC, GC/MS, 
GC/ECD and immunoassay. It has been shown that salivary THC reflects positive 
results in blood reliably even though the concentrations do not correlate specifically. 
(Schramm et al. 1992, 2; Samyn et al. 1999, 45.) 
 
With radio-labelled THC intravenous administration it has been shown that it is not 
likely that THC or its metabolites pass into the saliva or lungs from the blood. THC and 
its active metabolites are substantially plasma protein-bound. THC detected from saliva 
is therefore mostly from contamination of the buccal cavity during smoking. THC 
concentrations between 5 and 330 ng/ml have been detected from saliva after 8 hours 
since smoking. Analytical methods used for detecting THC are immunoassays and GC-
MS. According to Samyn et al, most immunoassays cross-react with THC and it’s other 
metabolites even though they are selective for the THC metabolite THC-COOH. 
(Schramm et al. 1992, 3;  Samyn et al. 1999, 45.) 
 
Samyn et al note that cannabinoid detection in saliva is a better indication of recent 
cannabis use than detection in urine. Even though the transport of cannabinoids from 
blood to saliva is minor they are easily detectable from saliva for several hours after 
administration via the usual routes of smoking and ingestion. The only problem with 
saliva testing is possible mouth washing if drinking beverages or other liquids after 
administration. In the review of Samyn et al they found one study (by Maseda, Hama, 
Fukui, Matsubara, Takahashi & Akane 1986) which shows that drinking beer lowers the 
salivary THC levels. In contrast other studies demonstrate that consumption of food or 
drink has no significant effect on THC levels. (Samyn et al. 1999, 45.) 
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3.2.6 Testing Saliva for Opioids 
 
In the early studies chemical and metabolic instability of heroin limited the 
measurement of morphine in saliva and other body fluids. First the detections were 
made with immunoassays and in those studies it was noted that saliva correlated badly 
with urine and that morphine could be detected longer in plasma than in saliva. In the 
review of Samyn et al they note that recently Goldberger et al have developed a new 
more sensitive method to quantify heroin and its metabolites MAM and morphine in 
body fluids. This method is based on solid phase extraction and GC/MS and it enables 
heroin to be detected after sniffing, smoking, and intravenous administration 
(Goldberger, Darwin, Grant, Alen, Caplan & Cone 1993). (Samyn et al. 1999, 46.) 
 
According to Schramm et al’s review methadone has been detected in saliva and the 
correlation between saliva and plasma is very good. In determination of codeine a 
higher concentration was found in saliva than in plasma after oral administration. There 
was much variation in codeine levels between individuals (Sharp, Wallace, Hindmarsh 
& Peel 1983). In another study it was found that there are similar concentrations of 
codeine in saliva and plasma (Cone 1990). Detection methods were different in these 
codeine studies. In the first study the analyses were conducted with GC and the other 
with RIA. Also differences can be caused by salivary pH which would affect the 
saliva/plasma ratio. (Schramm et al. 1992, 5.) 
 
3.2.7 Detection of Amphetamines in Saliva 
 
As Schramm et al states, saliva has been recommended to be the matrix for diagnostic 
evaluation because of the high amphetamine levels found in saliva and the strong 
dependency of urinary pH on the excretion of the drug. The amphetamine concentration 
in saliva is found to be three times higher than in plasma. (Schramm et al. 1992, 6.)  
 
Samyn et al has similar findings concerning amphetamine analysis. Amphetamine is 
bound to plasma proteins at about 16% and therefore is a mostly free component in 
blood. With GC/MS three times higher amphetamine concentrations in saliva than in 
plasma have been detected. They note that care must be taken when using 
immunoassays for amphetamine detection due to the risk of cross-reaction. Vapaatalo et 
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al had shown that TLC (Thin Layer Chromatography) is unsuitable for amphetamine 
detection because of the low sensitivity of the method. (Samyn et al. 1999, 47.) 
3.2.8 Detection of Benzodiazepines in Saliva 
 
Saliva can be used for detecting the use of benzodiazepines in on-site tests for roadside 
drug screening with a benzodiazepine quick tester even though the concentrations are 
generally low in saliva. Benzodiazepines are highly bound to proteins in blood and 
therefore they are not easily transferred to saliva. Also the problem with quick testers is 
the cross-reactivity of the benzodiazepine antibodies with other medicinal drugs. 
According to Pehrsson et al the need for a specific and sensitive tester is evident for 
roadside drug testing. (Pehrsson, Anna - Gunnar, Teemu - Engblom, Charlotta - Seppä, 
Heikki – Jama, Ahlam – Lillsunde, Pirjo 2007, 140-146.) 
 
In the study performed by Pehrsson et al they made an evaluation of saliva quick testers 
and compared the results to saliva and whole blood samples analysed with GC-MS. The 
result for saliva was that the sensitivity for benzodiazepines was 74.4%. Specificity was 
84.2% and accuracy 79.2%. They found the use of saliva for testing benzodiazepines 
promising and concluded that improvement can be made regarding saliva testing for 
benzodiazepines. (Pehrsson et al. 2007, 146-147.)   
 
 
4 PREVIOUS STUDIES OF COMPARING LEVELS OF DRUGS AND 
MEDICINES IN DIFFERENT MATRICES 
 
A number of different studies have been conducted comparing different drugs in 
different biological matrices. Mostly the matrices have been saliva and whole blood or 
plasma and saliva. Blood is a traditional and probably the most commonly used 
specimen when suspecting driving under the influence of drugs. Saliva on the other 
hand is widely used in quick-testers that police use when suspecting the abuse of drugs. 
Saliva is easy to collect in a non-invasive manner and it is easily processed for testing 
whereas blood sample requires more demanding specimen collection and handling. A 
blood sample must be taken by a medical professional and needs suitable surroundings.  
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In most of the studies I found the comparison was done with only a few substances that 
were determined beforehand. The voluntary subjects in the studies had to test negative 
in drug tests before the study. The amount of drugs given to them was strictly 
monitored. This differs quite a lot from my study since I don’t know what, when and 
how much the subjects have used drugs and in what manner. Here are two different 
studies performed to compare different matrices for analysing drugs. The studies have 
been executed in quite a different manner to each other. 
 
4.1 Comparison of Heroin and Cocaine Concentrations in Saliva with Concentrations 
in Blood and Plasma 
 
Amanda J. Jenkins, Jonathan M. Oyler, and Edward J. Cone from Addiction Research 
Center, National Institutes of Health in Baltimore conducted a study where they 
compared heroin and cocaine concentration in saliva to those in blood and plasma. In 
this study they also compared the results of administration of drugs via different routes. 
The subjects were administered three intravenous and three smoked doses of heroin. 
They were also administered one dose of cocaine smoked and one dose of cocaine 
intravenously. (Jenkins, Amanda – Oyler, Jonathan – Cone, Edward 1995, 359.) 
 
The subjects were healthy male volunteers with a history of drug use and they were 
required to test negative in drug tests before the study and pass physical and psychiatric 
evaluation. The study took place in a closed research unit of the Addiction Research 
Center. (Jenkins et al. 1995, 360.)  
 
Two of the subjects were administered heroin and seven of them cocaine. The 
administration of drug doses was scheduled so that the risk of carryover from previous 
doses was minimal and the safety of the subject was ensured. Samples were collected 30 
minutes before the drug administration and 0.03, 0.08, 0.17, 0.25, 0.5, 1, 2, 4, 8, 12, and 
24 hours after the administration of drugs. Saliva and blood samples were collected at 
the same time. The whole blood samples were collected in tubes containing sodium 
fluoride. Plasma samples were collected in tubes containing saturated sodium fluoride 
and acetic acid. Collection of blood samples was made with a syringe. For saliva 
samples the saliva flow was stimulated with sour candy containing citric acid. Saliva 
was collected by expectorating into a tube containing sodium fluoride. The samples 
were frozen at -30°C until the analysis took place. (Jenkins et al. 1995, 360-361.) 
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In heroin analysis blood and saliva were analysed for heroin and metabolites 6-
asetylmorphine and morphine by solid-phase extraction (SPE) and (gas 
chromatography-mass spectrometry) GC-MS. In cocaine analysis saliva and plasma 
samples were analysed for cocaine and metabolites AEME, benzoylecgonine (BZE), 
norbenzoylecgonine, norcocaine, cocaethylene, and norcocaethylene by SPE and GC-
MS. (Jenkins et al. 1995, 361.) 
 
As a result they found that heroin was detected in saliva at 2 minutes after the 
administration of drug by both routes. It seems that the concentration of heroin was 
higher and was detectible for longer in saliva after a smoked dose than in blood. The 
same usually happened with the metabolites. Only morphine was sometimes lower in 
saliva and was detected later than in blood. Peak heroin concentrations in saliva were 
different between routes due to the contamination of the oral cavity. After reaching their 
peak heroin concentrations in saliva decreased rapidly. All together heroin was 
detectable in saliva for 2-24 hours after smoking. (Jenkins et al. 1995, 361-364.) 
 
Peak heroin saliva concentrations declined rapidly after intravenous administration and 
reached the sensitivity limit of the assay between 5 and 30 minutes for most intravenous 
doses. For metabolites the peak concentrations were substantially lower and were 
achieved more slowly after intravenous administration. Concentrations of morphine in 
saliva were generally higher after smoking than after intravenous administration. 
(Jenkins et al. 1995, 364-365.) 
 
Heroin appeared rapidly in blood through both routes and peak concentrations were 
reached in 5 minutes. Generally higher heroin concentrations were found in blood after 
intravenous administration. Heroin concentrations declined rapidly in blood by both 
routes of administration and reached the sensitivity limit of the assay by 30 minutes. 
(Jenkins et al. 1995, 365.) 
  
According to their calculations the half-life of heroin in saliva after smoking was 
approximately 14-60 times longer than in blood. After intravenous administration the 
half-life of heroin is 2-208 times longer in saliva than in blood. (Jenkins et al. 1995, 
365-366.) 
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The cocaine and metabolites were analysed in saliva and plasma. After smoking the 
highest concentrations were detected after 2 minutes. After intravenous administration 
the peak concentration in saliva was reached in 5 to 30 minutes. Peak concentrations in 
saliva were lower after intravenous administration than smoking but cocaine was 
detected for longer in saliva after an intravenous dose. In plasma the peak cocaine 
concentrations were generally higher after intravenous administration than after 
smoking. Also in cocaine samples smoking resulted in high concentrations in saliva in 
the early collecting period due to the contamination of oral cavity. All together the half-
life of cocaine was shorter in saliva compared with plasma after smoking but longer 
after intravenous administration. (Jenkins et al. 1995, 366-371.) 
 
4.2 Amphetamine Concentrations in Saliva and in Whole Blood 
 
In another study, done by Charlotta Engblom, Teemu Gunnar, Anna Rantanen and Pirjo 
Lillsunde from the National Public Health Institute of Finland amphetamine 
concentrations in saliva and whole blood samples were compared. The study 
investigated amphetamine concentrations in oral fluid and whole blood samples from 
persons suspected of driving under the influence of drugs. The oral fluid samples were 
collected from persons that police suspected of drugged driving and they voluntarily 
took part in the study. Blood samples were collected by routine procedures. (Engblom, 
Charlotta – Gunnar, Teemu – Rantanen, Anna – Lillsunde, Pirjo 2007, 1.) 
 
The saliva samples were collected using an Intercept device. The collection pad was 
kept in the oral cavity for 3 minutes and then placed in the cup containing buffer 
solution. The samples were stored in -20 °C until they were analyzed. Blood samples 
were collected in tubes containing potassium oxalate and sodium fluoride. The samples 
were stored at 4 °C until analysed. Analyses were done with GC-MS. (Engblom et al. 
2007, 1-2.) 
 
They found that cases positive for amphetamine in whole blood were also positive in 
saliva. The concentrations of amphetamines were much higher in saliva than in whole 
blood. Also the detection time window in which the amphetamine was found was longer 
for saliva than whole blood. They concluded that saliva sample would be a suitable 
matrix for amphetamine when suspecting driving under the influence. 
(Engblom et al. 2007, 1-4.) 
   
  
19 
5 CONDUCTING THE STUDY 
 
My thesis will be answering the following questions: 
• What kind of differences there are between the concentrations of drugs and 
medicines of abuse in whole blood and plasma? 
• What kind of differences there are between the concentrations of drugs of abuse 
in whole blood and saliva? 
• What kind of differences there are between the concentrations of drugs of abuse 
in plasma and saliva? 
 
Handling of the samples has been as similar as possible so that the results would be 
comparable. Blood and plasma samples of each voluntary DUI driver have been first 
held in the fridge in +4 ºC and then put to freezer in -20 ºC at the same time. This way 
all the whole blood-plasma pairs should be well comparable. 
 
As written earlier in the thesis, the samples were collected at the Helsinki University 
Department of Forensic Medicine with forensic pathologist. Sampling took place in 
facilities provided specially for this project. Here are more detailed directions of how 
the samples are collected and handled.  
 
5.1 Sampling and Processing the Blood Samples  
 
According to National Public Health Institute sampling and sample processing 
guidelines, venous blood samples must primarily be taken from the elbow crook. 
Principally the vacuum technique is to be used. The open technique can also be used 
when necessary. The subject is normally in a sitting position when the samples are taken 
but the samples can also be taken from the subject when they are lying down. When 
taking a venous sample, the subject’s arm must be well supported, so that they can hold 
their arm as relaxed as possible. A tourniquet can be used for finding the vein if needed. 
The vein is found by looking and exploring with a finger. The puncture area must be 
cleaned with a dampened cloth, but the puncture area must be dry before piercing the 
skin. (Näytteenotto- ja näytteidenkäsittelyohje VTL-MO.K001 s.18) When taking 
intoxication samples, it is forbidden to use any solvents for cleaning the skin.  
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When using the vacuum technique to take the blood sample, the person taking the 
sample attaches a clean needle to the adapter and releases the needle cover. The needle 
is taken to the vein and a sample tube is connected to the other end of the adapter. The 
tourniquet must be loosened as soon as the blood starts to flow to the tube. Vacuum-
tubes fill themselves automatically to the needed volume. A new tube will be changed 
to the adapter after the previous is filled. After the last tube is released from the adapter, 
a cotton patch is placed on top of the puncture area and the needle is taken out of the 
vein. To stop the bleeding, pressure must be applied to the puncture area. The needle is 
released from the adapter and dropped to a needle container. (Näytteenotto- ja 
näytteidenkäsittelyohje VTL-MO.K001 s.18) When using a safety needle with wings, 
the needle cover is put on the needle after it has been taken out of the vein. The needle 
is released from the adapter and dropped to the container for used needles. 
 
According to National Public Health Institute drug laboratory intoxication investigation 
package instructions, you should always handle only one patient’s samples at the time. 
Each sample tube and clinical intoxication investigation form must be marked with an 
identifier label. The intoxication investigation form is filled with the required 
information and signed. Blood samples are taken to two gray-topped 10ml Venoject-
Glycaemia-VT-100SFX07 sample-tubes, so that there is at least 4ml blood in both of 
them. The tubes are turned upside down 7-8 times to ensure dissolving of the 
anticoagulant.     (Päihdetutkimuspakkauksen käyttöohje versio 1.0) 
 
For the DRUID-project two tubes of whole blood are first taken to Venoject-
Glycaemia-VT-100SFX07-tubes with 100mg of sodium fluoride and 22,50mg of 
potassium oxalate as additives. These are the routine sample tubes for a intoxication 
investigation. In addition one 10ml green-topped sodium heparin plasma tube 
(Venoject-Plasma-VT-100SH) is taken. For ethical reasons the plasma tube is taken 
after the routine samples even though this is against the manufacturers instructions. The 
tube is turned upside down at least 5 times. The plasma tube is allowed to cool down to 
room temperature for 15 minutes before centrifugation. Centrifugation happens with a 
speed of 3500 rpm for 10 minutes. After the centrifugation the plasma is separated to a 
gray-topped Venoject-Glycaemia-VT-100SFX07-tube with a Pasteur pipette. At least 
3ml of plasma is preferably taken.  
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The plasma samples are stored in the +4 ˚C until the whole blood sample results are 
ready from the routine analysis. When the whole blood sample is released from the 
routine lab I can take part of the sample for our purposes. At this point the whole blood 
and the plasma sample are frozen and stored at -20 ˚C until they are analysed. This way 
the storage environment is similar for both samples and it makes them more 
comparable. There were two whole blood samples for which I couldn’t take any for 
reanalysis because there were so little left from the routine analysis. These samples were 
numbers 93193 and 93197. In these cases the plasma sample has not been frozen but 
kept at fridge temperature the whole time. 
 
5.2 Collection and Handling of the Saliva Samples 
 
Saliva samples were collected with a Statsure saliva collection device. Saliva collection 
packages include a collection device with saliva collection pad and plastic 
transportation tube with 1ml of buffer solution. On the handle of the collection device 
there is an indicator window, which turns blue when the collector has enough saliva 
(1ml). (DRUID-tutkimussuunnitelma) 
 
According to the manufacturers instructions the collection package should not be used 
after the expiration date on the package. Subject’s identifier label is attached to the 
plastic tube. The tube is checked so that there is enough buffer solution, if not, the tube 
can not be used. (DRUID-tutkimussuunnitelma) 
 
At the beginning of the collection the collection device is taken out of the package. The 
subject collects saliva to the mouth as much as possible and the collection pad is placed 
under the tongue. The mouth is kept closed and timing begins. The collection device is 
not allowed to be moved inside the mouth during the collection and the collection pad is 
not allowed to be sucked or bitten. The collection device is kept in the mouth until the 
indicator window turns completely blue. Collection time varies between 2 and 5 
minutes. If the collection lasts over 5 minutes and the indicator does not turn blue, the 
collection should be put to a halt and a note of insufficient sample made. At the end the 
collection device is taken out of the mouth and put in to the plastic transportation tube. 
The collection device must not be put back in to the mouth after it has been in the buffer 
solution. The cap is pressed on to the transportation tube until you hear the click-sound. 
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Gently shake the tube so that the whole collection pad is saturated with the buffer 
solution. (DRUID-tutkimussuunnitelma) 
 
Samples should be transported to the laboratory within a day and be analysed within 3 
days. The samples must be stored at +4 ˚C. (DRUID-tutkimussuunnitelma) 
 
Since we are not able to analyse the samples within 3 days, the samples are stored in the 
freezer in -20 ˚ C until the analysing takes place. This way the samples were preserved 
as well as possible during the storage time.  
 
 
6 RESULTS 
 
The whole blood and plasma samples were de-frozen at fridge temperature +4 ˚C. De-
freezing did not happen without problems. Most of the whole blood tubes broke during 
the melting process. They were kept in the cover tube so that the sample was not lost 
but it made the processing of the sample more difficult for the laboratory analysts. 
Fortunately the analysis was successful and I got positive results for amphetamines, 
benzodiazepines or cannabinoids from 21 cases out of my original 28 cases. I chose to 
reanalyze cases in which there were positive results in amphetamines, benzodiazepines 
and cannabinoids in routine analysis. Only two whole blood samples 93190 and 93197 
were not analyzed again since there was not enough sample left. Plasma samples for 
these cases were analyzed according to the original routine results in the same manner 
as the other plasma samples also. Amphetamines, benzodiazepines and cannabinoids 
were chosen for reanalyzing because there were several positive results in the routine 
analysis so that there would be some comparison to be made.  
 
6.1 Amphetamine Results for Whole Blood and Plasma Samples 
 
The whole blood and plasma samples were analyzed with the quantitative amphetamine 
method using GC-MS at the National Public Health Institute routine laboratory. For all 
the samples I got two results from which I calculated the mean which then was used as a 
final result. There were 14 positive amphetamine results.   
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TABLE 2. Amphetamine Statistics 
 
  N 
Minimu
m 
Maximu
m Mean 
Std. 
Deviation 
Whole Blood-
Plasma Ratio 
Amphetamines 
14 ,75 1,13 1,0020 ,10818 
Plasma 
Amphetamines 14 23,44 1777,33 371,5396 519,84161 
Whole Blood 
Amphetamines 14 26,50 1841,24 385,5871 555,33304 
Valid N (listwise) 14         
 
As chart 2 shows there are no big differences between whole blood and plasma results 
for the amphetamines in general. Minimums and maximums are close to each other and 
the mean whole blood-plasma ratio is close to one. 
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TABLE 3. Concentrations of Amphetamines and Blood-Plasma Ratio 
 
  
Whole 
blood 
Amphetami
ne 
Plasma 
Amphetami
ne 
Whole 
Blood-
Plasma 
Ratio 
    
1 199,70 199,07 1,00 93160 
Total N 1 1 1 
1 214,68 287,10 ,75 93161 
Total N 1 1 1 
1 39,85 49,04 ,81 93163 
Total N 1 1 1 
1 148,86 138,51 1,07 93164 
Total N 1 1 1 
1 29,83 30,81 ,97 93182 
Total N 1 1 1 
1 156,17 155,12 1,01 93184 
Total N 1 1 1 
1 1841,24 1777,33 1,04 93185 
Total N 1 1 1 
1 214,85 226,57 ,95 93188 
Total N 1 1 1 
1 26,50 23,44 1,13 93190 
Total N 1 1 1 
1 1434,26 1293,50 1,11 93194 
Total N 1 1 1 
1 33,75 33,13 1,02 93189 
Total N 1 1 1 
1 590,80 538,15 1,10 93208 
Total N 1 1 1 
1 202,91 200,26 1,01 93209 
Total N 1 1 1 
1 264,85 249,56 1,06 93210 
Total N 1 1 1 
Case 
number 
Total N 14 14 14 
 
In chart 3 the individual paired samples with amphetamine results in whole blood and 
plasma can be seen. This shows the actual differences between whole blood and plasma 
samples in amphetamines. For the blood sample in case 93190 the result is from the 
original routine analyse and that sample has not been analysed again. Therefore there is 
some time gap between the whole blood and the plasma analysis. Apparently this has 
not had a significant effect on the results. In this chart the blood-plasma ratio which can 
also be seen indicates that the results are quite similar since the ratio is close to one. 
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CHART 1: Linearity of Amphetamine in Comparison of Whole Blood and Plasma 
 
Chart 1 shows the correlation of plasma and whole blood results. This linear curve 
shows that these two matrices correlate well for amphetamines. As a conclusion I can 
say that similar results are to be expected when comparing amphetamine concentrations 
in whole blood and plasma. 
 
6.2 Benzodiazepine Concentrations in Whole Blood and Plasma 
 
Benzodiazepines were analysed with a quantitative benzodiazepine method using GC-
MS. There were always two results from which I calculated the mean as a final result. 
All the analyses were conducted in the National Public Health Institute drug laboratory.  
 
In benzodiazepine-positive whole blood samples there were two samples that could not 
be analyzed again since there was too little sample left. In these cases (93197 and 
93190) plasma sample has been stored in the fridge temperature +4 ºC and was not 
frozen. Plasma results in these cases are compared with the original routine results. The 
time gap between the analyses is longer than in the other cases but the storage 
conditions are the same for whole blood and plasma. 
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Positive benzodiazepine results were detected for nordiazepam, oxazepam, temazepam, 
nitrazepam, clonazepam, diazepam, zopiclone, midazolam, and alprazolam. More than 
one positive result was found for diazepam, alprazolam, clonazepam, oxazepam, 
nordiazepam, and temazepam. These are therefore the substances I have concentrated 
on when comparing the matrices. 
 
TABLE 4. Whole Blood-Plasma Ratios for Benzodiazepines 
 
  N 
Minimu
m 
Maximu
m Mean 
Std. 
Deviation 
Whole Blood-
Plasma Ratio 
Diazepam 
12 ,46 ,71 ,5844 ,07124 
Whole Blood-
Plasma Ratio 
Alprazolam 
7 ,63 ,84 ,7403 ,07115 
Whole Blood-
Plasma Ratio 
Clonazepam 
6 ,49 ,83 ,6484 ,13348 
Whole Blood-
Plasma Ratio 
Oxazepam 
10 ,47 ,87 ,6390 ,11608 
Whole Blood-
Plasma Ratio 
Nordazepam 
12 ,47 ,69 ,5784 ,06646 
Whole Blood-
Plasma Ratio 
Temazepam 
8 ,49 ,80 ,6201 ,09734 
Valid N (listwise)          
 
Table 4 demonstrates the blood-plasma ratios for benzodiazepines. The minimum is 
0.46 for diazepam and the maximum is 0.87 for oxazepam. The mean ratio varies from 
0.5784 to 0.7403. In further detail the mean whole blood concentration for diazepam is 
58.4% of plasma concentration. The mean whole blood concentration for alprazolam is 
74% of plasma concentration. On average the whole blood concentration for the 
substances handled here is 63.5% of plasma concentration. 
 
   
  
27 
TABLE 5. Correlations of Blood and Plasma in Benzodiazepines 
 
  N 
Correlatio
n Sig. 
Pair 
1 
Blood Diazepam & 
Plasma Diazepam 12 ,999 ,000 
Pair 
2 
Blood Alprazolam & 
Plasma Alprazolam 7 ,998 ,000 
Pair 
3 
Blood Clonazepam & 
Plasma Clonazepam 6 ,894 ,016 
Pair 
4 
Blood Oxazepam & 
Plasma Oxazepam 10 ,998 ,000 
Pair 
5 
Blood Nordazepam 
& Plasma 
Nordazepam 
12 ,986 ,000 
Pair 
6 
Blood Temazepam & 
Plasma Temazepam 8 ,998 ,000 
 
 
In table 5 we can compare the correlations of different substances. Correlation is close 
to one so it is very strong in each of the substances. The difference is statistically 
significant since the significance number is small (sig> 0.01 and sig>0.05 for 
Clonazepam). This shows that the differences between the whole blood and plasma 
concentrations are not caused by chance but rather are consistent.  
 
As a conclusion I can say that the whole blood concentration for benzodiazepines is 
about 60% of that in plasma. The difference is quite consistent between different 
substances within the benzodiazepine group.  
 
6.3 Cannabinoid Concentrations in Whole Blood and Plasma 
 
Cannabinoids were also analysed in the National Public Health Institute drug laboratory 
with a quantitative GC-MS cannabis method. From two analysis results I again 
calculated the mean as the final result.  
 
Within the cases there were four samples with positive results for cannabinoids. The 
statistical analysis and comparison of the concentrations between whole blood and 
plasma have been done for THC and THC-COOH because these are the cannabinoids 
analysed for DRUID. For one case there was not enough sample left so whole blood 
results are from the original routine analysis. This sample is number 93190. As 
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mentioned before the plasma sample for that case has been stored at fridge temperature 
so that the storage conditions have been the same for whole blood and plasma. 
 
TABLE 6. THC and THC-COOH Concentrations in Whole Blood and Plasma 
 
  
Whole 
Blood 
THC 
Plasma 
THC 
Whole 
Blood-
Plasma 
Ratio 
THC 
Whole 
Blood 
THC-
COOH 
Plasma 
THC-
COOH 
Whole 
Blood-
Plasma 
ratio 
THC-
COOH 
Case 
number 
       
  93161 1 ,00 1,86 ,00 9,94 22,85 ,44 
    Total N 1 1 1 1 1 1 
  93189 1 1,97 3,22 ,61 31,68 62,22 ,51 
    Total N 1 1 1 1 1 1 
  93190 1 3,05 3,36 ,91 178,70 248,18 ,72 
    Total N 1 1 1 1 1 1 
  93212 1 ,00 ,00 . 6,51 14,47 ,45 
    Total N 1 1   1 1 1 
  Total N 4 4 3 4 4 4 
 
In table 6 we can see all the cannabinoid results for the studied cases. There are also the 
whole blood-plasma ratios in the table. There were only two cases with positive results 
in whole blood and in plasma for THC. So the blood-plasma ratio established for THC 
cannot really tell anything about THC blood-plasma ratios in general.  
 
For THC-COOH there were four cases with positive results. These four cases are still 
way too small a number of results to make any real interpretations about blood-plasma 
ratios and differences in concentrations but it can give some kind of hint about the 
reality. On average the blood-plasma ratio is 0.53 so the whole blood concentration is 
about 53% of the plasma concentration for THC-COOH. 
 
I didn’t see any point in making more statistical analyses for cannabinoids since there 
are not enough results. With a study group this size the results are not reliable and no 
interpretations can be made of the results. 
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6.4 Amphetamine Concentrations in Saliva Compared to Whole Blood and Plasma 
Concentrations 
 
The saliva samples were defrosted at room temperature. Samples were weighed to 
measure the actual amount of saliva in the collection tube. Analyses were made with a 
GC/MS semi quantitative method. For saliva samples only one analysis was made for 
each sample in comparison to blood and plasma for which there were always two 
parallel analyses done.  
 
I decided to go through amphetamine results for saliva as a whole and compare the 
outcomes together for plasma and whole blood since the results are so similar. I had 14 
amphetamine positive saliva samples.  
 
Amphetamine concentrations are significantly higher in saliva than in plasma or whole 
blood as seen in table 7. The mean whole blood amphetamine concentration in whole 
blood is about 3.8 % of the saliva concentration. Similarly the mean plasma 
amphetamine concentration is about 3.9 % of saliva concentration. With these results 
one has to keep in mind that the really high amphetamine concentrations in saliva are 
not as quantitative as other results since they are so much over the highest standard. 
 
TABLE 7. Descriptive Statistics of Amphetamines 
 
  N 
Minimu
m 
Maximu
m Mean 
Std. 
Deviation 
Whole Blood 
Amphetamine 14 26,5 1841,2 385,6 555,3 
Plasma 
Amphetamine 
 
14 23,4 1777,3 371,5 519,8 
Saliva Amphetamine 
 14 754,5 44363,1 10616,1 13509,1 
Whole Blood-Saliva 
ratio Amphetamine 14 ,01 ,06 ,038 ,02 
Plasma-Saliva ratio 
Amphetamine 14 ,01 ,06 ,039 ,02 
Valid N (listwise) 
 14         
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Correlations are shown in table 8. Correlations between saliva and plasma and also 
between saliva and whole blood are significant but not very strong (plasma-saliva 0,730 
is relatively close to one and whole blood saliva 0,739 is relatively close to one).   
 
TABLE 8. Amphetamine Correlations of Different Matrices 
 
  
Whole Blood 
Amphetamine 
Plasma 
Amphetamine 
Saliva 
Amphetami
ne 
Pearson 
Correlation 1,000 ,998
** ,739** 
Sig. (2-tailed)  ,000 ,003 
Whole Blood 
Amphetamine 
N 14 14 14 
Pearson 
Correlation ,998
** 1,000 ,730** 
Sig. (2-tailed) ,000  ,003 
Plasma Amphetamine 
N 14 14 14 
Pearson 
Correlation ,739
** ,730** 1,000 
Sig. (2-tailed) ,003 ,003  
Saliva Amphetamine 
N 14 14 14 
**. Correlation is significant at the 0.01 level (2-tailed).   
 
In table 9 there are individual amphetamine concentrations for each sample in whole 
blood, plasma and saliva. There are also ratios for whole blood and saliva as well as 
plasma and saliva. 
 
TABLE 9. Concentrations and Ratios of Amphetamine in Different Matrices 
 
  
Whole 
Blood 
Amph
etamin
e 
Plasma 
Amphet
amine 
Saliva 
Amphet
amine 
Whole 
Blood-
Saliva 
ratio 
Amphetam
ine 
Plasma-
Saliva 
ratio 
Amphetam
ine 
Case 
number 
       
  93160 1 199,7 199,1 5176,8 ,04 ,04 
    Total N 1 1 1 1 1 
  93161 1 214,7 287,1 11930,5 ,02 ,02 
    Total N 1 1 1 1 1 
  93163 1 39,9 49,0 754,5 ,05 ,06 
    Total N 1 1 1 1 1 
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  93164 1 148,9 138,5 7069,9 ,02 ,02 
    Total N 1 1 1 1 1 
  93182 1 29,8 30,8 796,2 ,04 ,04 
    Total N 1 1 1 1 1 
  93184 1 156,2 155,1 3193,5 ,05 ,05 
    Total N 1 1 1 1 1 
  93185 1 1841,2 1777,3 28558,5 ,06 ,06 
    Total N 1 1 1 1 1 
  93188 1 214,9 226,6 40167,0 ,05 ,06 
    Total N 1 1 1 1 1 
  93189 1 33,8 33,1 1216,9 ,03 ,03 
    Total N 1  1  1 1  1  
  93190 1 26,5 23,4 1467,4 ,02 ,02 
    Total N 1 1 1 1 1 
  93194 1 1434,3 1293,5 29140,8 ,05 ,04 
    Total N 1 1 1 1 1 
  93208 1 590,8 538,2 44363,1 ,01 ,01 
    Total N 1 1 1 1 1 
  93209 1 202,9 200,3 3564,8 ,06 ,06 
    Total N 1 1 1 1 1 
  93210 1 264,9 249,6 7375,9 ,04 ,03 
    Total N 1 1 1 1 1 
  Total N 14 14 14 14 14 
 
6.5 Cannabinoid Concentrations in Saliva Compared to Whole Blood and Plasma 
 
I had 9 THC positive saliva cases. Table 10 shows the descriptive measures for 
cannabioids. It is obvious that there are more cannabinoid positive cases in saliva than 
in whole blood or plasma. Also, THC concentrations are higher in saliva than in whole 
blood or plasma. Since there are not more comparable cases in cannabinoids I will not 
do any deeper analyses for these results.  
 
TABLE 10. THC Statistics 
  
  N 
Minimu
m 
Maximu
m Mean 
Std. 
Deviation 
Saliva THC 9 ,88 32,52 10,95 10,93 
Whole Blood 
THC 4 ,00 3,05 1,26 1,51 
Plasma THC 4 ,00 3,36 2,11 1,56 
Valid N 
(listwise) 3         
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In table 11 there are all the THC concentrations and whole blood-saliva and plasma-
saliva ratios. 
 
TABLE 11. THC Concentrations and Whole Blood-Saliva and Plasma-Saliva ratios 
 
  
Whole 
Blood 
THC 
Plasma 
THC 
Saliva 
THC 
THC 
Whole 
Blood-
Saliva 
Ratio 
THC 
Plasma-
Saliva 
Ratio 
Case 
number 
      
  93161 1 ,00 1,86 23,91 ,00 ,08 
    Total N 1 1 1 1 1 
  93163 1 . . 11,56 . . 
    Total N     1     
  93164 1 . . 13,02 . . 
    Total N     1     
  93166 1 . . ,88 . . 
    Total N     1     
  93189 1 1,97 3,22 32,52 ,06 ,10 
    Total N 1 1 1 1 1 
  93190 1 3,05 3,36 . . . 
    Total N 1 1       
  93196 1 . . 3,58 . . 
    Total N     1     
  93208 1 . . 9,04 . . 
    Total N     1     
  93210 1 . . 1,96 . . 
    Total N     1     
  93212 1 ,00 ,00 2,11 ,00 ,00 
    Total N 1 1 1 1 1 
  Total N 4 4 9 3 3 
 
6.6 Benzodiazepine Concentrations in Saliva Compared to Whole Blood and Plasma 
 
Comparable positive benzodiazepine results were detected for diazepam, alprazolam, 
clonazepam, oxazepam, nordiazepam, and temazepam. There were some individual 
positive results detected in saliva also for other substances in the Benzodiazepine group 
but I will be concentrating only on the ones from which can be done some comparison 
with plasma and whole blood results. 
 
Table 12 shows the whole blood-saliva ratios and table 13 plasma-saliva ratios from the 
benzodiazepines in question. 
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TABLE 12. Whole Blood-Saliva Ratios for Benzodiazepines 
 
  
Whole 
Blood-
Saliva 
Ratio 
Diazep
am 
Whole 
Blood-
Saliva 
Ratio 
Alpraz
olam 
Whole 
Blood-
Saliva 
Ratio 
Clonaz
epam 
Whole 
Blood-
Saliva 
Ratio 
Oxaze
pam 
Whole 
Blood-
Saliva 
Ratio 
Nordia
zepam 
Whole 
Blood-
Saliva 
Ratio 
Temaz
epam 
       
1 . ,17 . 10,89 45,05 5,48 93160 
Total N   1   1 1 1 
1 39,66 . . 7,16 29,44 5,52 93161 
Total N 1     1 1 1 
1 . ,67 ,21 . 35,50 . 93163 
Total N   1 1   1   
1 46,98 . . 13,69 46,11  93164 
Total N 1     1 1  
1 . 11,47 ,15 . . . 93165 
Total N   1 1       
1 58,38 4,35 . . 47,63 . 93166 
Total N 1 1     1   
1 18,54 2,97 . 4,03 35,13 10,27 93182 
Total N 1 1   1 1 1 
1 . . 5,88 . . . 93184 
Total N     1       
1 . 4,23 . . 39,15 . 93185 
Total N   1     1   
1 62,83 . 1,36 21,21 68,55 6,68 93188 
Total N 1   1 1 1 1 
1 . . . 7,08 . . 93189 
Total N       1     
1 1,28 . 6,66 4,66 24,73 1,42 93190 
Total N 1   1 1 1 1 
1 77,54 . . 13,56 66,27  93191 
Total N 1     1 1  
1 54,84 . . . 33,27 . 93195 
Total N 1       1   
1 23,06 5,15 . . 69,41 . 93197 
Total N 1 1     1   
Case 
number 
Total N 9 7 5 8 12 5 
 
Variation in the whole blood – saliva ratios seems to be quite large for each of the 
studied substances in the Benzodiazepines. In general the concentrations are mostly 
much higher in whole blood than in saliva for each substance with a few exceptions in 
alprazolam, clonazepam and temazepam. 
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TABLE 13. Plasma-Saliva Ratios for Benzodiazepines 
 
  
Plasma
-saliva 
ratio 
Diazep
am 
Plasma
-saliva 
ratio 
Alpraz
olam 
Plasma
-saliva 
ratio 
Clonaz
epam 
Plasma
-saliva 
ratio 
Oxaze
pam 
Plasma
-saliva 
ratio 
Nordia
zepam 
Plasma
-saliva 
ratio 
Temaz
epam 
       
1 . ,21 . 14,49 73,27 9,12 93160 
Total N   1   1 1 1 
1 78,28 . . 15,30 59,28 11,37 93161 
Total N 1     1 1 1 
1 . ,98 ,40 . 75,01 . 93163 
Total N   1 1   1   
1 65,74 . . 15,72 66,41  93164 
Total N 1     1 1  
1 . 13,58 ,18 . . . 93165 
Total N   1 1       
1 105,87 5,87 . . 90,45 . 93166 
Total N 1 1     1   
1 33,54 4,69 . 5,94 60,24 17,04 93182 
Total N 1 1   1 1 1 
1 . . 12,12 . . . 93184 
Total N     1       
1 . 5,48 . . 69,73 . 93185 
Total N   1     1   
1 110,65 . 1,83 29,98 116,78 10,61 93188 
Total N 1   1 1 1 1 
1 . . . 11,91 . . 93189 
Total N       1     
1 2,30 . 9,32 8,17 41,23 2,46 93190 
Total N 1   1 1 1 1 
1 134,89 . . 25,24 115,75  93191 
Total N 1     1 1  
1 82,31 . . . 60,96 . 93195 
Total N 1       1   
1 35,46 7,19 . . 101,25 ,37 93197 
Total N 1 1     1 1 
Case 
number 
Total N 9 7 5 8 12 6 
 
Similarly as in table 12 for whole blood - saliva we can see in table 13 that there is also 
quite a lot of variation in plasma – saliva ratios. As in blood also in plasma the 
concentrations are generally much higher than in saliva with a few exceptions in 
alprazolam, clonazepam and temazepam. 
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Table 14 and 15 shows the correlations between plasma and saliva and whole blood and 
saliva. 
 
TABLE 14. Plasma-Saliva Correlations for Benzodiazepines 
 
  N 
Correlatio
n Sig. 
Pair 
1 
Plasma & Saliva 
Diazepam 9 ,309 ,418 
Pair 
2 
Plasma & Saliva 
Alprazolam 7 ,232 ,616 
Pair 
3 
Plasma & Saliva 
Clonazepam 5 ,157 ,801 
Pair 
4 
Plasma & Saliva 
Oxazepam 8 ,934 ,001 
Pair 
5 
Plasma & Saliva 
Nordiazepam 12 ,892 ,000 
Pair 
6 
Plasma & Saliva 
Temazepam 6 ,920 ,009 
 
Plasma – saliva correlation is very good for oxazepam and it is statistically significant 
because the correlation is very close to one (0,934) and significance is very small, close 
to zero. Also nordiazepam and temazepam correlate well since their correlations are 
close to one also (0,892 and 0,920) and significances are close to zero for both. 
Contrastingly correlations for diazepam, alprazolam and clonazepam have no 
correlation what so ever. 
 
TABLE 15. Whole Blood-Saliva Correlations for Benzodiazepines 
 
  N 
Correlatio
n Sig. 
Pair 
1 
Whole Blood & 
Saliva Diazepam 9 ,296 ,439 
Pair 
2 
Whole Blood & 
Saliva Alprazolam 7 ,211 ,650 
Pair 
3 
Whole Blood & 
Saliva Clonazepam  5 ,074 ,906 
Pair 
4 
Whole Blood & 
Saliva Oxazepam 8 ,944 ,000 
Pair 
5 
Whole Blood & 
Saliva Nordiazepam 12 ,888 ,000 
Pair 
6 
Whole Blood & 
Saliva Temazepam 5 ,953 ,012 
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It seems the correlations are strong and statistically significant for oxazepam and 
nordiazepam also in whole blood – saliva comparison. For temazepam the correlation 
between whole blood and saliva appears to be strong too but it is not statistically that 
significant. Similarly as in plasma – saliva comparison diazepam, alprazolam and 
clonazepam have no correlation between whole blood and saliva. This would indicate 
that saliva is a more usable matrix for detecting oxazepam, nordiazepam or temazepam 
than diazepam, alprazolam or clonazepam. According to these results saliva gives no 
proper indication of the level of drugs in blood or plasma for these particular 
Benzodiazepines.  
 
  
CHART 2. Linearity of Nordiazepam in Saliva Compared to Whole Blood 
 
In chart 2 can be seen that saliva nordiazepam results are linear with whole blood 
nordiazepam results. This gives more indication of the correlation of these results. 
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CHART 3. Linearity of Oxazepam in Saliva Compared to Whole Blood 
 
Oxazepam also gives more indication of the correlation between saliva and whole blood 
with its linear regression. 
 
 
 
CHART 4: Linearity of Oxazepam in Saliva Compared to Plasma 
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As in whole blood – saliva comparison linearity of saliva – plasma also backs up the 
correlation results for oxazepam. This is visible in chart 4. 
 
 
 
CHART 5. Linearity of Nordiazepam in Saliva Compared to Plasma 
 
Chart 5 shows very well the linearity of nordiazepam in the comparison of saliva and 
plasma as was also well established for saliva – whole blood comparison. 
 
 
7 CONCLUSIONS 
 
7.1 Analysis of the Results 
 
The purpose of the research was to offer my commissioner, the National Public Health 
Institute, Druid project, information concerning the differences between the 
concentrations of drugs of abuse in different matrices. The matrices in question were 
whole blood, plasma and saliva. The goal was to collect the samples from more than 30 
voluntary suspected DUI drivers. Unfortunately I got samples from only 28 suspected 
DUI drivers. 
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Within the samples there were all together 14 positive cases for amphetamine. 
Amphetamine results were very promising as the results seemed to correlate very well. 
Even though the saliva concentrations were significantly higher the correlations to 
whole blood and plasma were good. Whole blood and plasma concentrations were very 
similar and whole blood-plasma ratios varied from 0.75 to 1.13 and the mean was 
1.002. Whole blood-saliva ratios varied from 0.01 to 0.33 with a mean of 0.07 and the 
plasma-saliva ratio varied from 0.01 to 0.41 with a mean of 0.08. 
 
As a result I can say that according to this research any of the matrices can be used to 
detect amphetamine from DUI drivers. The results are only suggestive since my sample 
is so small. But my results are in agreement with a previous study by Engblom et al. 
They concluded that saliva is a suitable matrix for detection of amphetamine from 
suspected DUI drivers for a comparison to whole blood. 
 
With larger sample number the results could be more generalized and proper rates could 
be calculated for the matrices. The results could indicate that amphetamine 
concentration could be analysed from any of the matrix in question and to calculate the 
concentration in others. 
 
Cannabinoids were detected only in four whole blood and plasma samples. Within the 
saliva samples there were nine cannabinoid positive samples. The amount of 
comparable samples was so small that no proper conclusions could be made. The only 
obvious result is that cannabinoids are more visible in saliva than in whole blood or 
plasma. This could be due to the fact that cannabinoids are usually consumed by 
smoking which may result in contamination of the oral cavity. According to my study I 
can not say how well saliva is suited for detection of cannabinoids from suspected DUI 
drivers. No rates between the matrices can be calculated with these results. A much 
bigger sample number would be needed to give any conclusions about the 
concentrations between different matrices. 
 
In benzodiazepines I got comparable positive results in six different substances. These 
were diazepam, alprazolam, clonazepam, nordiazepam, oxazepam and temazepam. 
Whole blood and plasma correlate well in each of the substances. This indicates that 
these matrices can both be used for detecting the benzodiazepines in question from 
suspected DUI drivers. 
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Saliva samples gave more conflicting results. From the same substances good 
correlations between whole blood and saliva and plasma and saliva were seen in 
nordiazepam, oxazepam and temazepam. Diazepam, alprazolam and clonazepam did 
not correlate at all. Again the sample was too small to make any definite conclusions 
about the ratios between different matrices. The concentrations varied quite lot between 
the matrices and substances studied. Variation in concentrations may be due to the fact 
that we don’t know when the substances have been consumed and in what dosages. 
According to these results I would conclude that saliva can not be used to measure the 
concentrations of benzodiazepines from suspected DUI drivers. A much bigger sample 
numbers would be needed to establish any proper ratios between the matrices. Even for 
the substances that seemed to correlate well between the matrices it would need a larger 
sample group to verify the results. It would also require specific knowledge about the 
substance that was suspected to have been abused to use saliva for measuring the 
concentration. 
 
7.2 Evaluation of the Research 
 
Validity  
The term validity is used to determine whether the research measures what it was 
supposed to measure (Uusitalo 1996, 84.). To increase validity I planned the research in 
close cooperation with my commissioner. The basis of my thesis is being done 
according to the sub study of larger entity. As my study is part of the bigger sub study, 
it is giving suggestive results for the main study and is therefore valid for the purpose it 
was planned for. Originally I attempted to get more results for a higher variety of 
substances. Since the final sample number was so small the validity also suffered. On 
the other hand the research measured what it was supposed to measure but on a smaller 
scale. All in all, I came to the conclusion that the validity in my research was not as 
high as I wanted it to be. This is largely due to the fact that it was more difficult to get 
samples that I had expected. 
 
Reliability 
The reliability of the research measures how dependable the results are, i.e. whether the 
same results would be achieved if the research was repeated (Uusitalo 1996, 84). The 
sample collection procedures and sample handling, storage and analysing procedures 
effect the reliability of my study. All the stages were done according to well determined 
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procedures. The study could be repeated and the results would probably be same or at 
least very similar. I would say that the reliability of the study is high even though some 
problems occurred in the thawing process of the whole blood and plasma samples and 
collecting sufficient amounts of some samples. 
 
7.3 My Own Reflections on the Thesis 
 
The whole thesis project started with the development assignment for school. As my 
development project I organised the sample collection facilities at the Helsinki 
University Department of Forensic Medicine and started the sample collection with the 
cooperation of a forensic pathologist in April 2008. This gave me a good starting point 
for my thesis since I was already familiar with the topic and the whole project that my 
thesis was based on. 
 
Difficulties arose with the sample collection. We were not able to get as many samples 
as we had hoped for. It was difficult to arrange sample collection times that were 
suitable for both the forensic pathologist and me. Also when we managed to arrange a 
time there weren’t as many suspected DUI drivers as we had hoped for. This was quite 
frustrating. 
 
I started to collect material for my thesis in June 2008 and at the same time I wrote the 
theoretical framework for the thesis. The theoretical part was ready in August 2008. 
Finding suitable articles was not too difficult since there were materials readily 
available at the National Public Health Institute, where I also worked.  
 
Sample collection took place during the whole summer. Originally I was supposed to 
get the samples to analysis during the summer and fall. Unfortunately there become 
problems with that and there were some delays with the analysis. Finally I got all the 
analyses results by mid December 2008. Statistical analyses were made as I got results. 
All statistical data was ready in the end of December 2008. 
 
The thesis project has been very educational since I had to familiarize myself with a 
topic with which I was not particularly well acquainted. I had not been in contact with 
drugs of abuse and driving under the influence of drugs and medicines. Also, saliva was 
not a familiar analytical matrix for me.  
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On the whole I found the project quite straight forward. It went on systematically and 
according to plan. The only thing that did not really work as planned was the time table. 
I was not able to get as many samples as I had hoped for. Also, the analyses were not 
finished in the time frame originally planned.        
 
During this project I was able to work in cooperation with different kinds of people. I 
think that the cooperation with the National Public Health Institute, Department of 
Forensic Medicine, and police worked quite well. Also, the suspected DUI drivers were 
positive about the study and most of them were happy to take part. All in all I think that 
this was a successful project which gave me lot of new skills and connections in 
working life.  
 
My thesis gives indicative results for the continuing project for the researchers at the 
National Public Health Institute. This topic needs further investigation and there is lot 
further to do with this subject. One further research objective is obviously continuing 
the study with more samples. Since The National Public Health Institute continues this 
study there will be many interesting results to get in the future. 
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Appendix 1           (1/2)  
List of substances analysed in DRUID-project and short description of each substance. 
1. Ethanol  
 
Ethanol, also called ethyl alcohol, is a flammable, colourless, 
chemical compound. It is best known as the type of alcohol 
found in alcoholic beverages and is also used as a solvent and 
antiseptic substance. In common use it is often referred to as 
alcohol. (Encyclopedia Britannica Online, 
http://search.eb.com/eb/article-9033143, 8.8.2008.) 
 
2. Morphine  
 
Morphine is one of the alkaloids that opium contains. Like 
other opioids, e.g., diacetylmorphine (heroin), morphine acts 
directly on the central nervous system to relieve pain. 
Generally, the term opioid has been used to refer to 
compounds with morphine-like activity. Effects on morphine 
use are for example analgesia, drowsiness, reduced 
gastrointestinal motility, miosis, nausea, and respiratory 
depression. Strong physical dependence may result in 
frequent use. (Samyn,Verstraete, van Haeren & Kintz 1999, 
45.) 
 
3. Amphetamine  
 
Amphetamine is a strong stimulant of the central nervous 
system. Amphetamine acts as indirect sympathomimetic 
drug. Amphetamine is used as drug of abuse and also as 
doping agent (Kraemer & Paul 2007, 1430). Amphetamine 
causes euphoria, increased energy, and alertness (Samyn et al 
1999, 47). 
 
4. MDMA  
 
MDMA is also known as ecstasy. It is an amphetamine-
derived designer drug. It produces a feeling of euphoria, 
energy and urges to socialize. As with other designer drugs it 
is used often as a “rave drug”. (Kraemer & Paul 2007, 1430.) 
 
5. MDA  
 
MDA is known as “love pills”. As for MDMA, MDA is also 
an amphetamine-derived designer drug and produces similar 
feelings. It is also used as a party drug. These drugs may lead 
to intoxication and impairment of ability to drive a car. 
(Kraemer & Paul 2007, 1430.) 
 
6. Cocaine  
 
Cocaine is derived from the leaves of the coca plant that 
grows in South America. For illegal abuse cocaine is sold as 
cocaine hydrochloride for oral, intravenous and intranasal use 
and also cocaine base (“crack”) for smoking. Cocaine 
produces a feeling of well-being and euphoria. (Samyn et al 
1999, 43-44.) 
 
7. THC  
 
THC is the primary psychoactive component in cannabis. 
Cannabis products are for example marijuana, hashish and 
hashish oil. Cannabis is the most widely produces plant-based 
illegal drug in the world. It is reported to be the most 
frequently used illegal drug in Europe and the USA. 
(Kraemer & Paul 2007,1426). Cannabis administration can 
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cause sedation, euphoria, hallucinations, and temporal 
distortion (Samyn et al 1999, 44.) 
 
8. THCCOOH  
 
THCCOOH is the inactive metabolite of THC. (Kraemer & 
Paul 2007, 1426.) 
9. Diazepam Diazepam is the most popular among the benzodiazepines 
and Valium is most widely known trademark for it. 
Benzodiazepines are tranquilizers. They are prescribed as 
sedative-hypnotics, muscle relaxants, anticonvulsants, and for 
relief of anxiety and psychiatric disorders. (Schramm, Smith, 
Craig & Kidwell 1992, 6.) 
 
10. Alprazolam Alprazolam belongs to benzodiazepines. It is used as 
medication for panic disorders and anxiety disorders. 
(Moffat, Osselton & Widdop 2004, 606.) 
 
11. Clonazepam  
 
Clonazepam belongs to benzodiazepines. It can be used for 
epilepsy, anxiety disorders, and panic disorders. (Moffat et al 
2004, 830.) 
 
12.Benzoylecgonine  
 
Benzoylecgonine is the primary metabolite of cocaine. It is 
further metabolized in to ecgonine. (Moffat et al 2004, 688.) 
 
13. Codeine  
 
Codeine is also an alkaloid that opium contains and it belongs 
to the group of opiates. Codeine is used commonly as an 
analgesic and antitussive. (Samyn, et al 1999, 45-46.) 
 
14.6-
acetylmorphine  
 
6-acetylmorhine known as MAM is active metabolite of 
heroin which is further hydrolyzed to morphine. (Samyn et al 
1999, 45.) 
 
15. 
Methamphetamine  
 
As with amphetamine, metamphetamine is also a strong 
stimulant of the central nervous system. Metamphetamine 
acts as an indirect sympathomimetic drug. Metamphetamine 
is used as drug of abuse and also as a doping agent. (Kraemer 
& Paul 2007, 1430.) 
16. Methadone  
 
Methadone is a synthetic opioid analgesic. It is used to 
administer opioid dependence. Methadone is usually taken 
orally or by intramuscular injection. To suppress the 
withdrawal symptoms initial doses are adequate. Use of 
methadone may cause dependence when the use lasts a long 
time. (Samyn et al 1999, 46.) 
17. Oxazepam 
 
Oxazepam is a metabolite of several benzodiazepines. It is 
used to treat for example anxiety disorders. (Moffat et al 
2004, 1376.) 
 
18. Nordiazepam  
 
Nordiazepam is a metabolite of many benzodiazepines and it 
is metabolized to oxazepam. (Moffat et al 2004, 1353.) 
19. Zopiclone 
 
Zopiclone is a benzodiazepine-like substance. It is used to 
treat insomnia. (Pharmaca Fennica 2005, 2969.) 
 
20. MDEA Similarly to MDA and MDMA, MDEA is also an 
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 amphetamine-derived designer drug. It is known as “Eve” 
and it is used similarly to other amphetamine-derived 
designer drugs. (Kraemer & Paul 2007, 1430.) 
 
21. Lorazepam 
 
Lorazepam belongs to the benzodiazepines and it is used to 
treat for example anxiety disorders. 
(http://www.drugs.com/lorazepam.html, 5.8.2008.) 
 
22. Flunitrazepam 
 
Flunitrazepam belongs to the group of benzodiazepines. It is 
used as a hypnotic to treat insomnia. (Moffat et al 2004, 
1045.) 
 
23. Zolpidem 
 
Zolpidem is a benzodiazepine-like substance. It is used to 
treat severe insomnia. (Pharmaca Fennica 2005, 2955.) 
 
24. Temazepam 
 
Temazepam is a metabolite of many benzodiazepines. It is 
used as a hypnotic to treat insomnia. (Moffat et al 2004, 
1603.) 
 
 
25. Midazolam 
 
 
Midazolam is a benzodiazepine derivative. It is used as a 
sedative and as premedication before anaesthesia. (Pharmaca 
Fennica 2005, 1693.) 
 
26. Phenazepam 
 
Phenazepam belongs to the group of benzodiazepines. It is 
used to treat for example epilepsy, alcohol withdrawal and 
insomnia. (http://en.wikipedia.org/wiki/Phenazepam, 
6.8.2008.) 
 
27. Nitrazepam 
 
Nitrazepam belongs to the group of benzodiazepines. It is 
mostly used to treat insomnia. (Moffat et al 2004, 1344.) 
 
28. Zaleplon 
 
Zaleplon is a benzodiazepine-like substance that is used to 
treat insomnia. (http://en.wikipedia.org/wiki/Zaleplon, 
6.8.2008.) 
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Appendix 2          (2/2)  
Sample collection form 
 
 
 
 
 
 
